Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04511013
Title	A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Southwest Oncology Group
Indications	melanoma
Therapies	Ipilimumab + Nivolumab Binimetinib + Encorafenib + Nivolumab
Age Groups:	adult \| senior
Covered Countries	USA